Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for Portal Hypertension in Cirrhosis
NCT02643212Phase 3Unknown
- Start
- May 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cirrhosis comparing Rivaroxaban with Placebo (2 arms). Primary endpoint: Survival free of transplant and decompensation / complications of portal hypertension at 24 months. Status: unknown.
02
Drugs
rivaroxaban
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on NCT02643212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02643212.